PLX-1000 is an investigational drug developed by Protalex, Inc. for the treatment of autoimmune diseases. It is designed to target and modulate the immune system, potentially reducing inflammation and improving symptoms in conditions like rheumatoid arthritis. The drug works by inhibiting specific pathways involved in the immune response, which may help restore balance in the immune system. Clinical trials are ongoing to evaluate its safety and effectiveness, with the hope of providing a new therapeutic option for patients suffering from chronic autoimmune disorders.